CURX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025
Revenue
0
0
0
0
Cost of Revenue
0
0
0
0
Gross Profit
0
0
0
0
Operating Expenses
3.3M
+4.5%
3.2M
+2.9%
3.1M
+225.1%
951.3K
R&D
2.6M
+15.0%
2.3M
-2.2%
2.3M
+240.4%
677.5K
SG&A
731.8K
-21.1%
927.2K
+17.9%
786.3K
+187.1%
273.9K
Operating Income
-3325560
-4.5%
-3183359
-2.9%
-3092639
-225.1%
-951327
EBITDA
-3325560
-4.5%
-3183359
-2.9%
-3092639
-225.1%
-951327
Net Income
-3290970
-4.5%
-3150228
-2.5%
-3073118
-222.1%
-954059
EPS (Basic)
$-2.40
-9.1%
$-2.20
-1.9%
$-2.16
-170.0%
$-0.80
EPS (Diluted)
$-2.40
-9.1%
$-2.20
-1.9%
$-2.16
-170.0%
$-0.80
Shares (Diluted)
1.4M
+0.1%
1.4M
-0.2%
1.4M
+10.9%
1.3M
Curanex Pharmaceuticals (CURX) โ€” Financials